Antonio
Fontanellas Roma
Profesional Investigador
Instituto de Investigación Sanitaria de Navarra
Pamplona, EspañaPublications in collaboration with researchers from Instituto de Investigación Sanitaria de Navarra (24)
2024
-
Exploring current and emerging therapies for porphyrias
Liver International, Vol. 44, Núm. 9, pp. 2174-2190
-
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)
Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284
-
Porphyrins and the porphyrias
Liver International
-
Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates
Gut
-
The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders
Cellular and Molecular Gastroenterology and Hepatology
2023
-
Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria
International Journal of Molecular Sciences, Vol. 24, Núm. 15
-
Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria
International Journal of Molecular Sciences, Vol. 24, Núm. 1
2022
-
Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria
British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3815-3830
-
Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 55-96
-
Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment
Life, Vol. 12, Núm. 11
2021
-
Acute intermittent porphyria, givosiran, and homocysteine
Journal of Inherited Metabolic Disease
-
Diagnosis and management of inborn errors of metabolism in adult patients in the emergency department
Diagnostics, Vol. 11, Núm. 11
-
Heme oxygenase-1 inducer hemin does not inhibit SARS-CoV-2 virus infection
Biomedicine and Pharmacotherapy, Vol. 137
-
High prevalence of insulin resistance in asymptomatic patients with acute intermittent porphyria and liver-targeted insulin as a novel therapeutic approach
Biomedicines, Vol. 9, Núm. 3, pp. 1-18
-
mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks
Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219
2020
-
Brain ventricular enlargement in human and murine acute intermittent porphyria
Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223
2019
-
Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model
Molecular Genetics and Metabolism, Vol. 128, Núm. 3, pp. 367-375
-
Messenger RNA therapy for rare genetic metabolic diseases
Gut, Vol. 68, Núm. 7, pp. 1323-1330
2018
-
Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909
2016
-
Emerging therapies for acute intermittent porphyria
Expert Reviews in Molecular Medicine, Vol. 18